Skip to main content
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1997 Apr;62(4):329–333. doi: 10.1136/jnnp.62.4.329

Risks of multiple sclerosis in relatives of patients in Flanders, Belgium.

H Carton 1, R Vlietinck 1, J Debruyne 1, J De Keyser 1, M B D'Hooghe 1, R Loos 1, R Medaer 1, L Truyen 1, I M Yee 1, A D Sadovnick 1
PMCID: PMC1074086  PMID: 9120443

Abstract

OBJECTIVES: To calculate age adjusted risks for multiple sclerosis in relatives of Flemish patients with multiple sclerosis. METHODS: Lifetime risks were calculated using the maximum likelihood approach. RESULTS: Vital information was obtained on 674 probands with multiple sclerosis in Flanders and a total of their 26225 first, second, and third degree relatives. Full medical information to allow documentation of multiple sclerosis status was available for 21351 (81.4%) relatives. The age adjusted risk for parents was 1.61 (SEM 0.35)%, for siblings 2.10 (SE 0.36)%, and for children 1.71 (SEM 0.70)%. For aunts and uncles, the risk was 0.66 (SEM 0.13)%. CONCLUSIONS: The risk for first degree relatives of patients with multiple sclerosis in Flanders is increased 10-fold to 12-fold; for second degree relatives, it is increased threefold. This information can be used for risk counselling in families and provides additional support for the role of more than one locus contributing to the susceptibility of multiple sclerosis.

Full text

PDF
330

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ebers G. C., Bulman D. E., Sadovnick A. D., Paty D. W., Warren S., Hader W., Murray T. J., Seland T. P., Duquette P., Grey T. A population-based study of multiple sclerosis in twins. N Engl J Med. 1986 Dec 25;315(26):1638–1642. doi: 10.1056/NEJM198612253152603. [DOI] [PubMed] [Google Scholar]
  2. Ebers G. C., Sadovnick A. D., Risch N. J. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature. 1995 Sep 14;377(6545):150–151. doi: 10.1038/377150a0. [DOI] [PubMed] [Google Scholar]
  3. Kurtzke J. F. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev. 1993 Oct;6(4):382–427. doi: 10.1128/cmr.6.4.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  5. Mumford C. J., Wood N. W., Kellar-Wood H., Thorpe J. W., Miller D. H., Compston D. A. The British Isles survey of multiple sclerosis in twins. Neurology. 1994 Jan;44(1):11–15. doi: 10.1212/wnl.44.1.11. [DOI] [PubMed] [Google Scholar]
  6. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  7. Reder A. T., Thapar M., Sapugay A. M., Jensen M. A. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunol. 1994 Oct;54(1-2):117–127. doi: 10.1016/0165-5728(94)90238-0. [DOI] [PubMed] [Google Scholar]
  8. Risch N. Estimating morbidity risks with variable age of onset: review of methods and a maximum likelihood approach. Biometrics. 1983 Dec;39(4):929–939. [PubMed] [Google Scholar]
  9. Robertson N. P., Fraser M., Deans J., Clayton D., Walker N., Compston D. A. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain. 1996 Apr;119(Pt 2):449–455. doi: 10.1093/brain/119.2.449. [DOI] [PubMed] [Google Scholar]
  10. Sadovnick A. D., Baird P. A., Ward R. H. Multiple sclerosis: updated risks for relatives. Am J Med Genet. 1988 Mar;29(3):533–541. doi: 10.1002/ajmg.1320290310. [DOI] [PubMed] [Google Scholar]
  11. Sadovnick A. D., Ebers G. C., Dyment D. A., Risch N. J. Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. Lancet. 1996 Jun 22;347(9017):1728–1730. doi: 10.1016/s0140-6736(96)90807-7. [DOI] [PubMed] [Google Scholar]
  12. Sadovnick A. D., Ebers G. C. Epidemiology of multiple sclerosis: a critical overview. Can J Neurol Sci. 1993 Feb;20(1):17–29. doi: 10.1017/s0317167100047351. [DOI] [PubMed] [Google Scholar]
  13. Sweeney V. P., Sadovnick A. D., Brandejs V. Prevalence of multiple sclerosis in British Columbia. Can J Neurol Sci. 1986 Feb;13(1):47–51. doi: 10.1017/s0317167100035782. [DOI] [PubMed] [Google Scholar]
  14. van Ooteghem P., D'Hooghe M. B., Vlietinck R., Carton H. Prevalence of multiple sclerosis in Flanders, Belgium. Neuroepidemiology. 1994;13(5):220–225. doi: 10.1159/000110383. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES